Prospective study on 13 cases of advanced prostate cancer was carried out. TNM stage, general clinical status, serum PSA level, histological type, Glieson's grade was registered. Castration and/or antiandrogen therapy (in most of the cases Flutamid) was performed. Two-ten (in average five) months after the start of the therapy re-biopsy, serum PSA control and general clinical examination was performed. The pre- and post-treatment histology involved HE, Apop-tag reaction to show apoptotic cells, Ps3, bcb, and Ki-67 immunostaining. The time elapsed from the second biopsy until the admission of this abstract varied between 5 and 21 months. The patients are being followed. Positive clinical reaction, manifested by regression or by steady state was observed at 10 patients. Increase of apoptotic index/from 1.5±0.2 to 8±1.2%, decrease of mitotic index was detected in these cases. One, clinically well-reactive patient showed only decrease in mitotic index, but not enhanced apoptosis. Serum PSA level decreased in all patients except in one fatal case. The three clinically non-responders (all died because of tumor shortly after the second biopsy) did not show increased apoptotic or decreased mitotic index. Ki-67 positivity was in good relation to mitotic activity. P53 or bcl2 expression did not relate to any type of clinical response or histological pattern. Apoptosis and mitosis index proved to be in correlation with clinical outcome in advanced prostate cancer, after surgical and/or chemical castration.
|Number of pages||1|
|Journal||British Journal of Urology|
|Issue number||SUPPL. 2|
|Publication status||Published - dec. 1 1997|
ASJC Scopus subject areas